Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment

F1000Res. 2019 Apr 23:8:F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019.


Endometriosis is an enigmatic disease that could start at birth. Its pathogenesis is supported by different theories. Accumulating facts relate it to a multigenic disorder. In this review of recent publications, the principal symptoms of the disease, pain and infertility, as well as its pathogenesis, diagnosis, and classification will be addressed. Endometriosis presents three main variants: superficial peritoneal disease, deep infiltrating endometriosis, and ovarian endometriomas. The management of the disease, surgery, and medical and alternative therapies will be discussed. Special reference will be made to the quality of surgery and how to understand patients with endometriosis and endometriosis.

Trial registration: ClinicalTrials.gov NCT01656434 NCT01728454 NCT01931670 NCT03204318.

Keywords: endometrosis deep infiltrating endometriosis pain infertility.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Dysmenorrhea
  • Endometriosis* / classification
  • Endometriosis* / diagnosis
  • Endometriosis* / therapy
  • Female
  • Humans
  • Infertility, Female*
  • Laparoscopy*

Associated data

  • ClinicalTrials.gov/NCT01656434
  • ClinicalTrials.gov/NCT01728454
  • ClinicalTrials.gov/NCT01931670
  • ClinicalTrials.gov/NCT03204318

Grants and funding

The author has received funding from Merck Sharp & Dohme Corp. (ClinicalTrials.gov Identifier: NCT01656434), Repros Therapeutics Inc. (ClinicalTrials.gov Identifier: NCT01728454), AbbVie (ClinicalTrials.gov Identifier: NCT01931670), and Myovant Sciences GmbH (ClinicalTrials.gov Identifier: NCT03204318).